Seeking Alpha

Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

RIDGE is Largest Natural History Study Conducted with More Than 175 Participants Enrolled to Date with Arrhythmogenic Right Ventricular Cardiomyopathy Due to Mutations in the PKP2 Gene Patients ...
Seeking Alpha

Tenaya Therapeutics, Inc. (TNYA) Discusses Initial Data From RIDGE-1 Phase Ib/II Trial of TN-401 Gene Therapy for ARVC Prepared Remarks Transcript

Hi, everyone, and thank you for joining us today. I'm Michelle Corral, Vice President of Corporate Communications and Investor Relations at Tenaya. Today, we are excited to present initial data from ...
WIVB-TV

Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

Large Majority of PKP2-associated ARVC Patients Appear Eligible for TN-401 Gene Therapy Based on Low Rates of Preexisting Immunity to AAV9 Antibodies SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- ...